Start for free
Start for free
Ikarian Capital logo

Ikarian Capital

North America, Texas, United States, Dallas

Description

We leverage our co-founder’s medical and financial background to invest both long and short in biotechnology and pharmaceuticals.

Investor Profile

Ikarian Capital has made 9 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Post Ipo Equity (67%)
  • Series Unknown (22%)
  • Series A (11%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Pharmaceutical
  • Medical
  • Genetics
  • Clinical Trials
  • Oncology
  • Robotics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ikarian Capital frequently co-invest with?

OrbiMed
OrbiMed
North America, New York, United States, New York
Co-Investments: 2
Surveyor Capital
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 2
Altium Capital
Altium Capital
North America, New York, United States, New York
Co-Investments: 3
CA
Cormorant Asset Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
Sio Capital Management
Sio Capital Management
North America, New York, United States, New York
Co-Investments: 2
Monashee Investment Management
Monashee Investment Management
North America, Massachusetts, United States, Boston
Co-Investments: 2
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund
Asia, Tel Aviv, Israel, Tel Aviv
Co-Investments: 2
Bain Capital Life Sciences
Bain Capital Life Sciences
North America, Massachusetts, United States, Boston
Co-Investments: 2
Janus Henderson Investors
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 2
Fidelity
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 2

What are some of recent deals done by Ikarian Capital?

Forte Biosciences

Sherman Oaks, California, United States

Forte Biosciences is a biotechnology company that focuses on dermatology.

BiotechnologyHealth CareLife SciencePharmaceutical
Post Ipo EquityNov 20, 2024
Amount Raised: $53,000,000
iBio

Newark, Delaware, United States

iBio is a technology platform that develops pharmaceutical product applications.

BiotechnologyGeneticsRoboticsTherapeutics
Post Ipo EquityMar 26, 2024
Amount Raised: $15,000,000
BioAtla

San Diego, California, United States

BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform.

BiotechnologyHealth CareMedical
Post Ipo EquitySep 29, 2021
Amount Raised: $75,000,000
Renovacor

Philadelphia, Pennsylvania, United States

Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.

BiotechnologyHealth CareLife Science
Post Ipo EquitySep 3, 2021
Amount Raised: $30,000,000
ValenzaBio

Bethesda, Maryland, United States

ValenzaBio is developing safe and effective treatment options for patients with autoimmune and inflammatory diseases.

BiopharmaBiotechnologyHealth CarePharmaceutical
Series AApr 8, 2021
Amount Raised: $79,374,978
X4 Pharmaceuticals

Cambridge, Massachusetts, United States

X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.

BiotechnologyClinical TrialsHealth CareOncologyPharmaceuticalTherapeutics
Post Ipo EquityMar 19, 2021
Amount Raised: $55,000,000
Kineta (Reverse Merger With Yumanity Therapeutics)

Boston, Massachusetts, United States

Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.

BiotechnologyHealth CareTherapeutics
Series UnknownDec 15, 2020
Amount Raised: $33,599,895
Solid Biosciences

Marlborough, Massachusetts, United States

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

BiotechnologyGeneticsHealth CareMedical
Post Ipo EquityDec 11, 2020
Amount Raised: $90,000,000
Immusoft

Seattle, Washington, United States

Immusoft is a biotechnology company that develops novel cell therapies for therapeutic protein delivery for rare diseases.

BiotechnologyHealth CareLife ScienceTherapeutics
Series UnknownSep 25, 2020
Amount Raised: $4,500,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator